Efficacy, Safety and Tolerability of Eziclen®/Izinova® Versus Klean-prep® on Bowel Cleansing in Adolescents Undergoing Colonoscopy

Last updated: March 1, 2021
Sponsor: Ipsen
Overall Status: Completed

Phase

3

Condition

Gastrointestinal Diseases And Disorders

Ulcers

Treatment

N/A

Clinical Study ID

NCT03008460
F-FR-58800-003
2016-002265-60
  • Ages 12-17
  • All Genders

Study Summary

The purpose of the protocol is to demonstrate that Eziclen®/Izinova®, an osmotic sulphate-based laxative preparation given on the day before colonoscopy has non-inferior efficacy to Klean-Prep® (polyethylene glycol (PEG)-electrolytes) on colon cleansing in adolescents aged 12 to 17 years (inclusive) with a body weight >40 kg, scheduled to undergo a colonoscopy for a routinely accepted diagnostic indication.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Provision of signed informed consent form to participate in the study obtained fromthe adolescent's parent(s)/ legal representative and a signed assent form from theadolescent according to local law
  • Male or female subjects between 12 to 17 years of age (inclusive)
  • Body weight more than 40 kg
  • Female of childbearing potential must have a negative pregnancy test
  • If female, and of child-bearing potential, subject must use an acceptable form ofbirth control (hormonal birth control, intrauterine device (IUD), double-barriermethod, or depot contraceptive)
  • Routinely accepted indication for undergoing colonoscopy, including but not limited topolyposis coli diagnosis or surveillance, gastrointestinal bleeding, unexplaineddiarrhoea or constipation, surveillance of inflammatory bowel disease or confirmationof mucosal healing, abdominal pain, abnormal endosonography or manometry, anaemia ofunknown aetiology, cancer surveillance
  • In the investigator's judgment, the parent(s)/legal representative are/is mentallycompetent to provide informed consent for the subject to participate in the study
  • In the investigator's judgement, subject is able and willing to follow studyprocedures including drug administration and response to questionnaires

Exclusion

Exclusion Criteria:

  • Subject with known or suspected ileus, gastrointestinal obstruction, gastric retention (gastroparesis), rectal impaction, toxic colitis, severe ulcerative colitis or toxicmegacolon, advanced carcinoma, swallowing disorders
  • Subject with known or suspected inflammatory bowel disease (Crohn's disease,ulcerative colitis) in moderate to severe active phase defined by Paediatric Crohn'sDisease Activity Index (PCDAI) >30 or Paediatric Ulcerative Colitis Index (PUCAI) >34
  • Subject with bowel perforation or increased risk of bowel perforation, includingconnective tissue disorders or recent bowel surgery
  • Subject with previous significant gastrointestinal surgery (e.g. colostomy, colectomy,gastric bypass, stomach stapling)
  • Subject with uncontrolled pre-existing electrolyte abnormalities, or with electrolyteabnormalities based on Visit 1 laboratory results such as hypernatremia, hyponatremia,hyperphosphatemia, hypokalaemia, hypocalcaemia, uncorrected dehydration, or secondaryto the use of medications such as diuretics or angiotensin converting enzymeinhibitors judged clinically significant by the investigator
  • Subject with a prior history or current condition of severe renal (estimatedglomerular filtration rate (GFR) less than 30 mL/min/1.73 m^2 as calculated by usingthe Schwartz bedside equation* [Schwartz et al, 2009]**), liver (ascites, Child-PughC), cardiac insufficiency (including congestive heart failure all grades) orhyperuricemia *The estimated GFR will be calculated in patients with elevated creatinine at baseline **Schwartz GJ and Work DF. Measurement and Estimation of GFR in Children andAdolescents. Clin J Am Soc Nephrol. 2009; 4: 1832-1843
  • Female subject who is pregnant or lactating
  • Subject who has participated in another investigational drug treatment within the last 90 days before the first study visit
  • Subject with phenylketonuria
  • Subject with history of asthma or hypersensitivity to any ingredient of either drugproduct
  • Subject for whom intake of substances likely to affect gastrointestinal motility orurinary flow rate is required
  • Subject with requirement to take any other oral medication within 3 hours of startingthe bowel preparation, as this may impact medication absorption
  • Subject with tendency for nausea and/or vomiting
  • Subject with impaired consciousness that predisposes them to pulmonary aspiration orwho have known swallowing disorders
  • Subject with history of major medical/psychiatric conditions that, in the judgment ofthe investigator, would compromise safety in the study
  • Subject with mental or psychiatric condition rendering the subject unable tounderstand the nature, scope and possible consequences of the study, and/or evidenceof an uncooperative attitude
  • Subject with a condition that, in the opinion of the investigator, might increase therisk to the subject or decrease the chance of obtaining satisfactory data needed toachieve the objectives of the study
  • Subject who has previous enrolment in this study or concomitant enrolment in otherclinical studies

Study Design

Total Participants: 250
Study Start date:
October 15, 2017
Estimated Completion Date:
June 29, 2020

Connect with a study center

  • Fakultní nemocnice Královské Vinohrady

    Praha, 100 34
    Czechia

    Site Not Available

  • Všeobecná fakultní nemocnice v Praze

    Praha, 128 08
    Czechia

    Site Not Available

  • Université de Picardie Jules Verne

    Amiens, 80054
    France

    Site Not Available

  • Hôpital Femme Mère-Enfant

    Bron, 69677
    France

    Site Not Available

  • CHU de Lille - Hôpital Jeanne de Flandre

    Lille, 59037
    France

    Site Not Available

  • Hôpital Necker Enfants Malades

    Paris, 75015
    France

    Site Not Available

  • Uniklinikum Essen

    Essen, 45147
    Germany

    Site Not Available

  • Evang Krankenhaus Hamm

    Hamm, 59063
    Germany

    Site Not Available

  • Universitätsklinikum Leipzig, Klinik und Poliklinik für Kinder- und Jugendmedizin

    Leipzig, 04103
    Germany

    Site Not Available

  • Klinikum Ulm

    Ulm, 89075
    Germany

    Site Not Available

  • HELIOS Klinikum Wuppertal

    Wuppertal, 42283
    Germany

    Site Not Available

  • ORN Santobono-Pausilipon Padiglione Santobono

    Napoli, 680 122
    Italy

    Site Not Available

  • Ospedale "Spirito Santo" U.D.C.

    Pescara, 65125
    Italy

    Site Not Available

  • Azienda Ospedaliero-Universitaria Sant'Andrea

    Roma, 00189
    Italy

    Site Not Available

  • Noord West Ziekenhuisgroep

    Alkmaar, 1814 HB
    Netherlands

    Site Not Available

  • AMC Emma kinderziekenhuis

    Amsterdam, 1105 AZ
    Netherlands

    Site Not Available

  • Maasstad ziekenhuis

    Rotterdam, 3079 DZ
    Netherlands

    Site Not Available

  • Maxima Medisch Centrum

    Veldhoven, 5504 DB
    Netherlands

    Site Not Available

  • Copernicus Podmiot Leczniczy Sp. z.o.o

    Gdańsk, 80-803
    Poland

    Site Not Available

  • Samodzielny Publiczny Szpital Kliniczny Nr 6 Śląskiego

    Katowice, 40-752
    Poland

    Site Not Available

  • Uniwersytecki Szpital Dziecięcy w Krakowie

    Kraków, 30-663
    Poland

    Site Not Available

  • Uniwersytecki Dziecięcy Szpital Kliniczny im. L. Zamenhofa w Białymstoku

    Lublin, 20-093
    Poland

    Site Not Available

  • Uniwersytecki Szpital Dziecięcy w Lublinie

    Lublin, 20-093
    Poland

    Site Not Available

  • Instytut "Pomnik - Centrum Zdrowia Dziecka"

    Warszawa, 04-730
    Poland

    Site Not Available

  • Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wrocławiu

    Wrocław, 50-369
    Poland

    Site Not Available

  • Samodzielny Publiczny Szpital Kliniczny Nr 1

    Zabrze, 41-800
    Poland

    Site Not Available

  • Instytut Centrum Zdrowia Matki Polki

    Łódź, 93-338
    Poland

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.